Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 236930, 21 pages
http://dx.doi.org/10.1155/2014/236930
Review Article

Pharmacological Strategies to Prevent Contrast-Induced Acute Kidney Injury

Nephrology Unit, Department of Medicine, Faculty of Medicine, Thammasat University (Rangsit Campus), Klong Luang, Pathumtani 12121, Thailand

Received 19 October 2013; Revised 3 January 2014; Accepted 7 January 2014; Published 26 February 2014

Academic Editor: Michele Andreucci

Copyright © 2014 Pattharawin Pattharanitima and Adis Tasanarong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Berns, “Nephrotoxicity of contrast media,” Kidney International, vol. 36, no. 4, pp. 730–740, 1989. View at Google Scholar · View at Scopus
  2. M. R. Rudnick, S. Goldfarb, and J. Tumlin, “Contrast-induced nephropathy: is the picture any clearer?” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 261–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. ACT Investigators, “Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT),” Circulation, vol. 124, no. 11, pp. 1250–1259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. S. Gurm, D. E. Smith, O. Berwanger et al., “Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 5, no. 1, pp. 98–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Tepel, P. Aspelin, and N. Lameire, “Contrast-induced nephropathy: a clinical and evidence-based approach,” Circulation, vol. 113, no. 14, pp. 1799–1806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Goldenberg and S. Matetzky, “Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies,” CMAJ, vol. 172, no. 11, pp. 1461–1471, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Fishbane, J. H. Durham, K. Marzo, and M. Rudnick, “N-acetylcysteine in the prevention of radiocontrast-induced nephropathy,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 251–260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. G. Gleeson and S. Bulugahapitiya, “Contrast-induced nephropathy,” The American Journal of Roentgenology, vol. 183, no. 6, pp. 1673–1689, 2004. View at Google Scholar · View at Scopus
  9. M. Maeder, M. Klein, T. Fehr, and H. Rickli, “Contrast nephropathy: review focusing on prevention,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1763–1771, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. W. Murphy, B. J. Barrett, and P. S. Parfrey, “Contrast nephropathy,” Journal of the American Society of Nephrology, vol. 11, no. 1, pp. 177–182, 2000. View at Google Scholar · View at Scopus
  11. H. S. Thomsen and S. K. Morcos, “Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines,” British Journal of Radiology, vol. 76, no. 908, pp. 513–518, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. Gami and V. D. Garovic, “Contrast nephropathy after coronary angiography,” Mayo Clinic Proceedings, vol. 79, no. 2, pp. 211–219, 2004. View at Google Scholar · View at Scopus
  13. M. R. Rudnick, S. Goldfarb, L. Wexler et al., “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol cooperative study,” Kidney International, vol. 47, no. 1, pp. 254–261, 1995. View at Google Scholar · View at Scopus
  14. B. R. C. Kurnik, L. S. Weisberg, I. M. Cuttler, and P. B. Kurnik, “Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure,” Journal of Laboratory and Clinical Medicine, vol. 116, no. 1, pp. 27–35, 1990. View at Google Scholar · View at Scopus
  15. J.-P. Bonvalet, P. Pradelles, and N. Farman, “Segmental synthesis and actions of prostaglandins along the nephron,” The American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 253, no. 3, part 2, pp. F377–F387, 1987. View at Google Scholar · View at Scopus
  16. Y. Agmon, H. Peleg, Z. Greenfeld, S. Rosen, and M. Brezis, “Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat,” Journal of Clinical Investigation, vol. 94, no. 3, pp. 1069–1075, 1994. View at Google Scholar · View at Scopus
  17. R. V. Freeman, M. O'Donnell, D. Share et al., “Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose,” The American Journal of Cardiology, vol. 90, no. 10, pp. 1068–1073, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Nikolsky, R. Mehran, D. Turcot et al., “Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention,” The American Journal of Cardiology, vol. 94, no. 3, pp. 300–305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Gruberg, G. S. Mintz, R. Mehran et al., “The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency,” Journal of the American College of Cardiology, vol. 36, no. 5, pp. 1542–1548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. P. B. Persson, P. Hansell, and P. Liss, “Pathophysiology of contrast medium-induced nephropathy,” Kidney International, vol. 68, no. 1, pp. 14–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Brezis and S. Rosen, “Mechanisms of disease: hypoxia of the renal medulla—its implications for disease,” The New England Journal of Medicine, vol. 332, no. 10, pp. 647–655, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Tumlin, F. Stacul, A. Adam et al., “Pathophysiology of contrast-induced nephropathy,” The American Journal of Cardiology, vol. 98, no. 6, supplement 1, pp. 14–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Romano, C. Briguori, C. Quintavalle et al., “Contrast agents and renal cell apoptosis,” European Heart Journal, vol. 29, no. 20, pp. 2569–2576, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Weisbord and P. M. Palevsky, “Prevention of contrast-induced nephropathy with volume expansion,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 273–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Mueller, G. Buerkle, H. J. Buettner et al., “Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty,” Archives of Internal Medicine, vol. 162, no. 3, pp. 329–336, 2002. View at Google Scholar · View at Scopus
  26. P. Aspelin, P. Aubry, S.-G. Fransson, R. Strasser, R. Willenbrock, and K. J. Berg, “Nephrotoxic effects in high-risk patients undergoing angiography,” The New England Journal of Medicine, vol. 348, no. 6, pp. 491–499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. T. S. Larson, K. Hudson, and J. I. Mertz, “Renal vasoconstrictive response to contrast medium. The role of sodium balance and the renin-angiotensin system,” Journal of Laboratory and Clinical Medicine, vol. 101, no. 3, pp. 385–391, 1983. View at Google Scholar · View at Scopus
  28. T. Yoshioka, A. Fogo, and J. K. Beckman, “Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion,” Kidney International, vol. 41, no. 4, pp. 1008–1015, 1992. View at Google Scholar · View at Scopus
  29. C. M. Erley, N. Heyne, S. Rossmeier, T. Vogel, T. Risler, and H. Osswald, “Adenosine and extracellular volume in radiocontrast media-induced nephropathy,” Kidney International, Supplement, vol. 54, no. 67, pp. S192–S194, 1998. View at Google Scholar · View at Scopus
  30. R. Solomon, C. Werner, D. Mann, J. D'Elia, and P. Silva, “Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents,” The New England Journal of Medicine, vol. 331, no. 21, pp. 1416–1420, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. A. J. Taylor, D. Hotchkiss, R. W. Morse, and J. McCabe, “PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction,” Chest, vol. 114, no. 6, pp. 1570–1574, 1998. View at Google Scholar · View at Scopus
  32. H. S. Trivedi, H. Moore, S. Nasr et al., “A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity,” Nephron. Clinical practice, vol. 93, no. 1, pp. C29–C34, 2003. View at Google Scholar · View at Scopus
  33. B. Dussol, S. Morange, A. Loundoun, P. Auquier, and Y. Berland, “A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients,” Nephrology Dialysis Transplantation, vol. 21, no. 8, pp. 2120–2126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Cho, N. Javed, D. Traub, S. Kodali, F. Atem, and V. Srinivasan, “Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease,” Journal of Interventional Cardiology, vol. 23, no. 5, pp. 460–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 19, pp. 2328–2334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Recio-Mayoral, M. Chaparro, B. Prado et al., “The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention. The RENO study,” Journal of the American College of Cardiology, vol. 49, no. 12, pp. 1283–1288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. S. Jang, H. Y. Jin, J. S. Seo et al., “Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury—a systematic review and meta-analysis,” Circulation Journal, vol. 76, no. 9, pp. 2255–2265, 2012. View at Google Scholar
  38. S. E. Hogan, P. L'Allier, S. Chetcuti et al., “Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis,” The American Heart Journal, vol. 156, no. 3, pp. 414–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Kanbay, A. Covic, S. G. Coca, F. Turgut, A. Akcay, and C. R. Parikh, “Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials,” International Urology and Nephrology, vol. 41, no. 3, pp. 617–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. D. Navaneethan, S. Singh, S. Appasamy, R. E. Wing, and A. R. Sehgal, “Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” The American Journal of Kidney Diseases, vol. 53, no. 4, pp. 617–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Zoungas, T. Ninomiya, R. Huxley et al., “Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy,” Annals of Internal Medicine, vol. 151, no. 9, pp. 631–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Kunadian, A. Zaman, I. Spyridopoulos, and W. Qiu, “Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials,” European Journal of Radiology, vol. 79, no. 1, pp. 48–55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Cotgreave, P. Moldeus, and I. Schuppe, “The metabolism of N-acetylcysteine by human endothelial cells,” Biochemical Pharmacology, vol. 42, no. 1, pp. 13–16, 1991. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Parvez, M. A. Rahman, and R. Moncada, “Contrast media-induced lipid peroxidation in the rat kidney,” Investigative Radiology, vol. 24, no. 9, pp. 697–702, 1989. View at Google Scholar · View at Scopus
  45. G. L. Bakris, N. Lass, A. O. Gaber, J. D. Jones, and J. C. Burnett Jr., “Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals,” The American Journal of Physiology—Renal Fluid and Electrolyte Physiology, vol. 258, no. 1, pp. F115–F120, 1990. View at Google Scholar · View at Scopus
  46. R. Baliga, N. Ueda, P. D. Walker, and S. V. Shah, “Oxidant mechanisms in toxic acute renal failure,” The American Journal of Kidney Diseases, vol. 29, no. 3, pp. 465–477, 1997. View at Google Scholar · View at Scopus
  47. M. Tepel, M. van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek, “Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine,” The New England Journal of Medicine, vol. 343, no. 3, pp. 180–184, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. K.-G. Shyu, J.-J. Cheng, and P. Kuan, “Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure,” Journal of the American College of Cardiology, vol. 40, no. 8, pp. 1383–1388, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kay, W. H. Chow, T. M. Chan et al., “Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 5, pp. 553–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. J. G. Webb, G. E. Pate, K. H. Humphries et al., “A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect,” The American Heart Journal, vol. 148, no. 3, pp. 422–429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Birck, S. Krzossok, F. Markowetz, P. Schnülle, F. J. van der Woude, and C. Braun, “Acetylcysteine for prevention of contrast nephropathy: meta-analysis,” The Lancet, vol. 362, no. 9384, pp. 598–603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. D. W. Isenbarger, S. M. Kent, and P. G. O'Malley, “Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy,” The American Journal of Cardiology, vol. 92, no. 12, pp. 1454–1458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Alonso, J. Lau, B. L. Jaber, A. Weintraub, and M. J. Sarnak, “Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials,” The American Journal of Kidney Diseases, vol. 43, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. M. Bagshaw and W. A. Ghali, “Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic reveiw and meta-analysis,” BMC Medicine, vol. 2, article 38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Pannu, B. Manns, H. Lee, and M. Tonelli, “Systematic review of the impact of N-acetylcysteine on contrast nephropathy,” Kidney International, vol. 65, no. 4, pp. 1366–1374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. H. Duong, T. A. MacKenzie, and D. J. Malenka, “N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis,” Catheterization and Cardiovascular Interventions, vol. 64, no. 4, pp. 471–479, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Liu, D. Nair, J. Ix, D. H. Moore, and S. Bent, “N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” Journal of General Internal Medicine, vol. 20, no. 2, pp. 193–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. A. M. Kelly, B. Dwamena, P. Cronin, S. J. Bernstein, and R. C. Carlos, “Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy,” Annals of Internal Medicine, vol. 148, no. 4, pp. 284–294, 2008. View at Google Scholar · View at Scopus
  59. C. S. Kwok, C. L. Pang, J. K. Yeong, and Y. K. Loke, “Measures used to treat contrast-induced nephropathy: overview of reviews,” British Journal of Radiology, vol. 86, no. 1021, Article ID 20120272, 2013. View at Google Scholar
  60. A. V. Kshirsagar, C. Poole, A. Mottl et al., “N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 761–769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Misra, K. Leibowtiz, R. M. Gowda, M. Shapiro, and I. A. Khan, “Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis,” Clinical Cardiology, vol. 27, no. 11, pp. 607–610, 2004. View at Google Scholar · View at Scopus
  62. B. K. Nallamothu, K. G. Shojania, S. Saint et al., “Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis,” The American Journal of Medicine, vol. 117, no. 12, pp. 938–947, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Zagler, M. Azadpour, C. Mercado, and C. H. Hennekens, “N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials,” The American Heart Journal, vol. 151, no. 1, pp. 140–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. D. A. Gonzales, K. J. Norsworthy, S. J. Kern et al., “A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity,” BMC Medicine, vol. 5, article 32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Sun, Q. Fu, L. Cao, W. Jin, L. Cheng, and Z. Li, “Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials,” PLoS ONE, vol. 8, no. 1, Article ID e55124, 2013. View at Google Scholar
  66. N. Grosser, A. Hemmerle, G. Berndt et al., “The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells,” Free Radical Biology and Medicine, vol. 37, no. 12, pp. 2064–2071, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. L. L. Stoll, M. L. McCormick, G. M. Denning, and N. L. Weintraub, “Antioxidant effects of statins,” Drugs of Today, vol. 40, no. 12, pp. 975–990, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. J.-K. Park, D. N. Muller, E. M. A. Mervaala et al., “Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects,” Kidney International, vol. 58, no. 4, pp. 1420–1430, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Gueler, S. Rong, J.-K. Park et al., “Postischemic acute renal failure is reduced by short-term statin treatment in a rat model,” Journal of the American Society of Nephrology, vol. 13, no. 9, pp. 2288–2298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. C. M. Mangano, L. S. Diamondstone, J. G. Ramsay, A. Aggarwal, A. Herskowitz, and D. T. Mangano, “Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization,” Annals of Internal Medicine, vol. 128, no. 3, pp. 194–203, 1998. View at Google Scholar · View at Scopus
  71. N. Attallah, L. Yassine, J. Musial, J. Yee, and K. Fisher, “The potential role of statins in contrast nephropathy,” Clinical Nephrology, vol. 62, no. 4, pp. 273–278, 2004. View at Google Scholar · View at Scopus
  72. S. Khanal, N. Attallah, D. E. Smith et al., “Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions,” The American Journal of Medicine, vol. 118, no. 8, pp. 843–849, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Xinwei, F. Xianghua, Z. Jing et al., “Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention,” The American Journal of Cardiology, vol. 104, no. 4, pp. 519–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S.-H. Jo, B.-K. Koo, J.-S. Park et al., “Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study,” The American Heart Journal, vol. 155, no. 3, pp. 499–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Özhan, I. Erden, S. Ordu et al., “Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography,” Angiology, vol. 61, no. 7, pp. 711–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Toso, M. Maioli, M. Leoncini et al., “Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease,” The American Journal of Cardiology, vol. 105, no. 3, pp. 288–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Patti, E. Ricottini, A. Nusca et al., “Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial,” The American Journal of Cardiology, vol. 108, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Quintavalle, D. Fiore, F. de Micco et al., “Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury,” Circulation, vol. 126, no. 25, pp. 3008–3016, 2012. View at Google Scholar
  79. Y. Han, G. Zhu, L. Han et al., “Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease,” Journal of the American College of Cardiology, vol. 63, no. 1, pp. 62–70, 2014. View at Publisher · View at Google Scholar
  80. M. Leoncini, A. Toso, M. Maioli, F. Tropeano, S. Villani, and F. Bellandi, “Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study),” Journal of the American College of Cardiology, vol. 63, no. 1, pp. 71–79, 2014. View at Publisher · View at Google Scholar
  81. B.-C. Zhang, W.-M. Li, and Y.-W. Xu, “High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis,” Canadian Journal of Cardiology, vol. 27, no. 6, pp. 851–858, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Zhou, W. J. Yuan, N. Zhu, and L. Wang, “Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” Clinical Nephrology, vol. 76, no. 6, pp. 475–483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Zhang, L.-H. Shen, L.-H. Hu, and B. He, “Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” The American Journal of Nephrology, vol. 33, no. 4, pp. 344–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. I. Durak, H. Özbek, M. Karaayvaz, and H. S. Öztürk, “Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity,” Drug and Chemical Toxicology, vol. 25, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Lloberas, J. Torras, I. Herrero-Fresneda et al., “Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment,” The FASEB Journal, vol. 16, no. 8, pp. 908–910, 2002. View at Google Scholar · View at Scopus
  86. B. H. Ali, “Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research,” Food and Chemical Toxicology, vol. 41, no. 11, pp. 1447–1452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O'Neill, “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality,” The American Journal of Medicine, vol. 103, no. 5, pp. 368–375, 1997. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Spargias, E. Alexopoulos, S. Kyrzopoulos et al., “Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 110, no. 18, pp. 2837–2842, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Boscheri, C. Weinbrenner, B. Botzek, K. Reynen, E. Kuhlisch, and R. H. Strasser, “Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction,” Clinical Nephrology, vol. 68, no. 5, pp. 279–286, 2007. View at Google Scholar · View at Scopus
  90. S.-H. Jo, B.-K. Koo, J.-S. Park et al., “N-acetylcysteine versus AScorbic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study-a prospective randomized controlled trial,” The American Heart Journal, vol. 157, no. 3, pp. 576–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Zhou and H. Chen, “Prevention of contrast-induced nephropathy with ascorbic acid,” Internal Medicine, vol. 51, no. 6, pp. 531–535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Brueck, H. Cengiz, R. Hoeltgen et al., “Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial,” Journal of Invasive Cardiology, vol. 25, no. 6, pp. 276–283, 2013. View at Google Scholar
  93. A. Tasanarong, D. Piyayotai, and S. Thitiarchakul, “Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study,” Journal of the Medical Association of Thailand, vol. 92, no. 10, pp. 1273–1281, 2009. View at Google Scholar · View at Scopus
  94. A. Tasanarong, A. Vohakiat, P. Hutayanon, and D. Piyayotai, “New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures,” Nephrology Dialysis Transplantation, vol. 28, no. 2, pp. 337–344, 2013. View at Google Scholar
  95. T. M. Kitzler, A. Jaberi, G. Sendlhofer et al., “Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial,” Wiener Klinische Wochenschrift, vol. 124, no. 9-10, pp. 312–319, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. R. J. Workman, M. I. Shaff, R. V. Jackson, J. Diggs, M. G. Frazer, and C. Briscoe, “Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog,” Investigative Radiology, vol. 18, no. 2, pp. 160–166, 1983. View at Google Scholar · View at Scopus
  97. S. N. Heyman, M. Brezis, F. H. Epstein, K. Spokes, P. Silva, and S. Rosen, “Early renal medullary hypoxic injury from radiocontrast and indomethacin,” Kidney International, vol. 40, no. 4, pp. 632–642, 1991. View at Google Scholar · View at Scopus
  98. U. Elkayam, T. M. H. Ng, P. Hatamizadeh, M. Janmohamed, and A. Mehra, “Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action,” Circulation, vol. 117, no. 2, pp. 200–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Kapoor, N. Sinha, R. K. Sharma et al., “Use of dopamine in prevention of contrast induced acute renal failure—a randomised study,” International Journal of Cardiology, vol. 53, no. 3, pp. 233–236, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. S. S. Hans, B. A. Hans, R. Dhillon, C. Dmuchowski, and J. Glover, “Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency,” The American Surgeon, vol. 64, no. 5, pp. 432–436, 1998. View at Google Scholar · View at Scopus
  101. A. S. Abizaid, C. E. Clark, G. S. Mintz et al., “Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency,” The American Journal of Cardiology, vol. 83, no. 2, pp. 260–263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  102. M. A. Stevens, P. A. McCullough, K. J. Tobin et al., “A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation,” Journal of the American College of Cardiology, vol. 33, no. 2, pp. 403–411, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Allaqaband, R. Tumuluri, A. M. Malik et al., “Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy,” Catheterization and Cardiovascular Interventions, vol. 57, no. 3, pp. 279–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. G. W. Stone, P. A. McCullough, J. A. Tumlin et al., “Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2284–2291, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. T. M. H. Ng, S. W. Shurmur, M. Silver et al., “Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN),” International Journal of Cardiology, vol. 109, no. 3, pp. 322–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. L. J. Arend, G. L. Bakris, J. C. Burnett Jr., C. Megerian, and W. S. Spielman, “Role for intrarenal adenosine in the renal hemodynamic response to contrast media,” Journal of Laboratory and Clinical Medicine, vol. 110, no. 4, pp. 406–411, 1987. View at Google Scholar · View at Scopus
  107. W. Huber, K. Ilgmann, M. Page et al., “Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study,” Radiology, vol. 223, no. 3, pp. 772–779, 2002. View at Google Scholar · View at Scopus
  108. W. Huber, C. Schipek, K. Ilgmann et al., “Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency,” The American Journal of Cardiology, vol. 91, no. 10, pp. 1157–1162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. W. Huber, F. Eckel, M. Hennig et al., “Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study,” Radiology, vol. 239, no. 3, pp. 793–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Baskurt, B. Okcun, O. Abaci et al., “N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy,” European Journal of Clinical Investigation, vol. 39, no. 9, pp. 793–799, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Kinbara, T. Hayano, N. Ohtani, Y. Furutani, K. Moritani, and M. Matsuzaki, “Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy,” Journal of Cardiology, vol. 55, no. 2, pp. 174–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. M. E. Bilasy, M. A. Oraby, H. M. Ismail, and F. A. Maklady, “Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures,” Journal of Interventional Cardiology, vol. 25, no. 4, pp. 404–410, 2012. View at Google Scholar
  113. J. H. Ix, C. E. McCulloch, and G. M. Chertow, “Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis,” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2747–2753, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. B. Dai, Y. Liu, L. Fu, Y. Li, J. Zhang, and C. Mei, “Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials,” The American Journal of Kidney Diseases, vol. 60, no. 3, pp. 360–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S. M. Bagshaw and W. A. Ghali, “Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1087–1093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. S. S. Sule and W. Frishman, “Nebivolol: new therapy update,” Cardiology in Review, vol. 14, no. 5, pp. 259–264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Veverka, D. S. Nuzum, and J. L. Jolly, “Nebivolol: a third-generation β-adrenergic blocker,” Annals of Pharmacotherapy, vol. 40, no. 7-8, pp. 1353–1360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. O. Toprak, M. Cirit, M. Tanrisev et al., “Preventive effect of nebivolol on contrast-induced nephropathy in rats,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 853–859, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Avci, M. Yeşil, S. Bayata, N. Postaci, E. Arikan, and M. Cirit, “The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction,” Anadolu Kardiyoloji Dergisi, vol. 11, no. 7, pp. 613–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. Ö. Günebakmaz, M. G. Kaya, F. Koc et al., “Does nebivolol prevent contrast-induced nephropathy in humans?” Clinical Cardiology, vol. 35, no. 4, pp. 250–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. C.-L. Huang, J. Lewicki, L. K. Johnson, and M. G. Cogan, “Renal mechanism of action of rat atrial natriuretic factor,” Journal of Clinical Investigation, vol. 75, no. 2, pp. 769–773, 1985. View at Google Scholar · View at Scopus
  122. M. Nakamoto, J. I. Shapiro, P. F. Shanley, L. Chan, and R. W. Schrier, “In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure,” Journal of Clinical Investigation, vol. 80, no. 3, pp. 698–705, 1987. View at Google Scholar · View at Scopus
  123. K. B. Margulies, L. J. McKinley, P. G. Cavero, and J. C. Burnett Jr., “Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure,” Kidney International, vol. 38, no. 6, pp. 1101–1108, 1990. View at Google Scholar · View at Scopus
  124. B. R. C. Kurnik, R. L. Allgren, F. C. Center, R. J. Solomon, E. R. Bates, and L. S. Weisberg, “Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy,” The American Journal of Kidney Diseases, vol. 31, no. 4, pp. 674–680, 1998. View at Google Scholar · View at Scopus
  125. S. Morikawa, T. Sone, H. Tsuboi et al., “Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide,” Journal of the American College of Cardiology, vol. 53, no. 12, pp. 1040–1046, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. R. C. Harris, “Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney,” Transactions of the American Clinical and Climatological Association, vol. 124, pp. 139–151, 2013. View at Google Scholar
  127. D. Schlondorff, “Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins,” The American Journal of Medicine, vol. 81, no. 2B, pp. 1–11, 1986. View at Publisher · View at Google Scholar · View at Scopus
  128. W. Krause, P. Muschick, and U. Krüger, “Use of near-infrared reflection spectroscopy to study the effects of x-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors,” Investigative Radiology, vol. 37, no. 12, pp. 698–705, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. M. S. Paller and J. C. Manivel, “Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect,” Kidney International, vol. 42, no. 6, pp. 1345–1354, 1992. View at Google Scholar · View at Scopus
  130. D. Grekas, H. Kalekou, and A. Tourkantonis, “Effect of prostaglandin E2 (PGE2) in the prevention of acute renal failure in anesthetized dogs. In situ renal preservation,” Renal Failure, vol. 11, no. 1, pp. 27–31, 1989. View at Google Scholar · View at Scopus
  131. L. Gurkowski, M. MacDougall, and T. Wiegmann, “Effects of misoprostol on contrast-induced renal dysfunction,” The American Journal of Therapeutics, vol. 2, no. 11, pp. 837–842, 1995. View at Google Scholar
  132. K. Spargias, E. Adreanides, E. Demerouti et al., “Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 120, no. 18, pp. 1793–1799, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Boccalandro, M. Amhad, R. W. Smalling, and S. Sdringola, “Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast,” Catheterization and Cardiovascular Interventions, vol. 58, no. 3, pp. 336–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. V. O. Gomes, C. E. Poli de Figueredo, P. Caramori et al., “N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial,” Heart, vol. 91, no. 6, pp. 774–778, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. E. E. Ozcan, S. Guneri, B. Akdeniz et al., “Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial,” The American Heart Journal, vol. 154, no. 3, pp. 539–544, 2007. View at Publisher · View at Google Scholar · View at Scopus